Jeffrey L Curtis, Lori A Bateman, Susan Murray, David J Couper, Wassim W Labaki, Christine M Freeman, Kelly B Arnold, Stephanie A Christenson, Neil E Alexis, Mehmet Kesimer, Richard C Boucher, Robert J Kaner, Igor Barjaktarevic, Christopher B Cooper, Eric A Hoffman, R Graham Barr, Eugene R Bleecker, Russell P Bowler, Alejandro Comellas, Mark T Dransfield, Michael B Freedman, Nadia N Hansel, Jerry A Krishnan, Nathaniel Marchetti, Deborah A Meyers, Jill Ohar, Wanda K O'Neal, Victor E Ortega, Robert Paine Iii, Stephen P Peters, Benjamin M Smith, Jadwiga A Wedzicha, J Michael Wells, Prescott G Woodruff, MeiLan K Han, Fernando J Martinez
{"title":"慢性阻塞性肺病早期进展 SPIROMICS 研究的设计：SOURCE 研究。","authors":"Jeffrey L Curtis, Lori A Bateman, Susan Murray, David J Couper, Wassim W Labaki, Christine M Freeman, Kelly B Arnold, Stephanie A Christenson, Neil E Alexis, Mehmet Kesimer, Richard C Boucher, Robert J Kaner, Igor Barjaktarevic, Christopher B Cooper, Eric A Hoffman, R Graham Barr, Eugene R Bleecker, Russell P Bowler, Alejandro Comellas, Mark T Dransfield, Michael B Freedman, Nadia N Hansel, Jerry A Krishnan, Nathaniel Marchetti, Deborah A Meyers, Jill Ohar, Wanda K O'Neal, Victor E Ortega, Robert Paine Iii, Stephen P Peters, Benjamin M Smith, Jadwiga A Wedzicha, J Michael Wells, Prescott G Woodruff, MeiLan K Han, Fernando J Martinez","doi":"10.15326/jcopdf.2023.0490","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The biological mechanisms leading some tobacco-exposed individuals to develop early-stage chronic obstructive pulmonary disease (COPD) are poorly understood. This knowledge gap hampers development of disease-modifying agents for this prevalent condition.</p><p><strong>Objectives: </strong>Accordingly, with National Heart, Lung and Blood Institute support, we initiated the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Study of Early COPD Progression (SOURCE), a multicenter observational cohort study of younger individuals with a history of cigarette smoking and thus at-risk for, or with, early-stage COPD. Our overall objectives are to identify those who will develop COPD earlier in life, characterize them thoroughly, and by contrasting them to those not developing COPD, define mechanisms of disease progression.</p><p><strong>Methods/discussion: </strong>SOURCE utilizes the established SPIROMICS clinical network. Its goal is to enroll n=649 participants, ages 30-55 years, all races/ethnicities, with ≥10 pack-years cigarette smoking, in either Global initiative for chronic Obstructive Lung Disease (GOLD) groups 0-2 or with preserved ratio-impaired spirometry; and an additional n=40 never-smoker controls. Participants undergo baseline and 3-year follow-up visits, each including high-resolution computed tomography, respiratory oscillometry and spirometry (pre- and postbronchodilator administration), exhaled breath condensate (baseline only), and extensive biospecimen collection, including sputum induction. Symptoms, interim health care utilization, and exacerbations are captured every 6 months via follow-up phone calls. An embedded bronchoscopy substudy involving n=100 participants (including all never-smokers) will allow collection of lower airway samples for genetic, epigenetic, genomic, immunological, microbiome, mucin analyses, and basal cell culture.</p><p><strong>Conclusion: </strong>SOURCE should provide novel insights into the natural history of lung disease in younger individuals with a smoking history, and its biological basis.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11548966/pdf/","citationCount":"0","resultStr":"{\"title\":\"Design of the SPIROMICS Study of Early COPD Progression: SOURCE Study.\",\"authors\":\"Jeffrey L Curtis, Lori A Bateman, Susan Murray, David J Couper, Wassim W Labaki, Christine M Freeman, Kelly B Arnold, Stephanie A Christenson, Neil E Alexis, Mehmet Kesimer, Richard C Boucher, Robert J Kaner, Igor Barjaktarevic, Christopher B Cooper, Eric A Hoffman, R Graham Barr, Eugene R Bleecker, Russell P Bowler, Alejandro Comellas, Mark T Dransfield, Michael B Freedman, Nadia N Hansel, Jerry A Krishnan, Nathaniel Marchetti, Deborah A Meyers, Jill Ohar, Wanda K O'Neal, Victor E Ortega, Robert Paine Iii, Stephen P Peters, Benjamin M Smith, Jadwiga A Wedzicha, J Michael Wells, Prescott G Woodruff, MeiLan K Han, Fernando J Martinez\",\"doi\":\"10.15326/jcopdf.2023.0490\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The biological mechanisms leading some tobacco-exposed individuals to develop early-stage chronic obstructive pulmonary disease (COPD) are poorly understood. This knowledge gap hampers development of disease-modifying agents for this prevalent condition.</p><p><strong>Objectives: </strong>Accordingly, with National Heart, Lung and Blood Institute support, we initiated the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Study of Early COPD Progression (SOURCE), a multicenter observational cohort study of younger individuals with a history of cigarette smoking and thus at-risk for, or with, early-stage COPD. Our overall objectives are to identify those who will develop COPD earlier in life, characterize them thoroughly, and by contrasting them to those not developing COPD, define mechanisms of disease progression.</p><p><strong>Methods/discussion: </strong>SOURCE utilizes the established SPIROMICS clinical network. Its goal is to enroll n=649 participants, ages 30-55 years, all races/ethnicities, with ≥10 pack-years cigarette smoking, in either Global initiative for chronic Obstructive Lung Disease (GOLD) groups 0-2 or with preserved ratio-impaired spirometry; and an additional n=40 never-smoker controls. Participants undergo baseline and 3-year follow-up visits, each including high-resolution computed tomography, respiratory oscillometry and spirometry (pre- and postbronchodilator administration), exhaled breath condensate (baseline only), and extensive biospecimen collection, including sputum induction. Symptoms, interim health care utilization, and exacerbations are captured every 6 months via follow-up phone calls. An embedded bronchoscopy substudy involving n=100 participants (including all never-smokers) will allow collection of lower airway samples for genetic, epigenetic, genomic, immunological, microbiome, mucin analyses, and basal cell culture.</p><p><strong>Conclusion: </strong>SOURCE should provide novel insights into the natural history of lung disease in younger individuals with a smoking history, and its biological basis.</p>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11548966/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.15326/jcopdf.2023.0490\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15326/jcopdf.2023.0490","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
Design of the SPIROMICS Study of Early COPD Progression: SOURCE Study.
Background: The biological mechanisms leading some tobacco-exposed individuals to develop early-stage chronic obstructive pulmonary disease (COPD) are poorly understood. This knowledge gap hampers development of disease-modifying agents for this prevalent condition.
Objectives: Accordingly, with National Heart, Lung and Blood Institute support, we initiated the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Study of Early COPD Progression (SOURCE), a multicenter observational cohort study of younger individuals with a history of cigarette smoking and thus at-risk for, or with, early-stage COPD. Our overall objectives are to identify those who will develop COPD earlier in life, characterize them thoroughly, and by contrasting them to those not developing COPD, define mechanisms of disease progression.
Methods/discussion: SOURCE utilizes the established SPIROMICS clinical network. Its goal is to enroll n=649 participants, ages 30-55 years, all races/ethnicities, with ≥10 pack-years cigarette smoking, in either Global initiative for chronic Obstructive Lung Disease (GOLD) groups 0-2 or with preserved ratio-impaired spirometry; and an additional n=40 never-smoker controls. Participants undergo baseline and 3-year follow-up visits, each including high-resolution computed tomography, respiratory oscillometry and spirometry (pre- and postbronchodilator administration), exhaled breath condensate (baseline only), and extensive biospecimen collection, including sputum induction. Symptoms, interim health care utilization, and exacerbations are captured every 6 months via follow-up phone calls. An embedded bronchoscopy substudy involving n=100 participants (including all never-smokers) will allow collection of lower airway samples for genetic, epigenetic, genomic, immunological, microbiome, mucin analyses, and basal cell culture.
Conclusion: SOURCE should provide novel insights into the natural history of lung disease in younger individuals with a smoking history, and its biological basis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
